Parkinson’s disease (PD) is one of the major neurodegenerative diseases (ND) which presents a progressive neurodegeneration characterized by loss of dopamine in the substantia nigra pars compacta. It is well known that oxidative stress, inflammation and glutamatergic pathway play key roles in the development of PD. However, therapies remain uncertain and research for new treatment is mandatory. This review focuses on the potential effects of lithium, as a potential therapeutic strategy, on PD and some of the presumed mechanisms by which lithium provides its benefit properties. Lithium medication downregulates GSK-3beta, the main inhibitor of the WNT/β-catenin pathway. The stimulation of the WNT/β-catenin could be associated with the control of oxidative stress, inflammation, and glutamatergic pathway. Future prospective clinical trials could focus on lithium and its different and multiple interactions in PD.

中文翻译：

---

帕金森病：锂通过靶向 WNT/β-连环蛋白途径、氧化应激、炎症和谷氨酸途径的潜在作用

帕金森病（PD）是主要的神经退行性疾病（ND）之一，其呈现以黑质致密部多巴胺丧失为特征的进行性神经变性。众所周知，氧化应激、炎症和谷氨酸通路在PD的发生发展中发挥着关键作用。然而，治疗方法仍然不确定，新治疗方法的研究是强制性的。本综述重点关注锂作为一种潜在的治疗策略对帕金森病的潜在影响，以及锂提供其有益特性的一些推测机制。锂药物下调 GSK-3beta（WNT/β-catenin 通路的主要抑制剂）。WNT/β-连环蛋白的刺激可能与氧化应激、炎症和谷氨酸能途径的控制有关。未来的前瞻性临床试验可能会重点关注锂及其在帕金森病中的不同和多种相互作用。